EGFR and non-small cell lung carcinoma: On May 21, 2021, the FDA approved amivantamab for treating patients with locally advanced or metastatic NSCLC harboring the EGFR ex20ins mutation whose disease progressed on or after platinum-based chemotherapy50,51.